Trader sentiment on Encore Medical's IPO closing market cap remains tightly contested, with implied probabilities near 40% for sub-$45 million valuation and 35% for no listing before June 2026, reflecting uncertainty over execution amid modest fundamentals. Recent S-1/A amendments and a free writing prospectus in early April 2026 signal active roadshow efforts for a proposed $15 million raise at $5 per share via 3 million shares on NYSE American, yet absence of firm pricing or debut confirmation—despite mid-April hype targeting May 6—fuels delay bets. Differentiators include 49% trailing-twelve-month revenue growth to $2.1 million from EU sales of its CE-marked PFO closure device, versus persistent $1.6 million net losses, high regulatory exposure from U.S. FDA pivotal trial (targeted 2027 completion), and competition from Abbott and W.L. Gore in the $1.5 billion stroke prevention segment. A pricing announcement could tip odds toward the 45M–50M bin; further postponement favors the no-IPO outcome.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated<45M 40%
No IPO before June 2026 35%
45M–50M 18%
50M–55M 3.6%
$15,088 Vol.
$15,088 Vol.
Apr 22, 2026
<45M
40%
45M–50M
18%
50M–55M
4%
55M+
3%
No IPO before June 2026
35%
<45M 40%
No IPO before June 2026 35%
45M–50M 18%
50M–55M 3.6%
$15,088 Vol.
$15,088 Vol.
Apr 22, 2026
<45M
$6,273 Vol.
40%
45M–50M
$1,720 Vol.
18%
50M–55M
$910 Vol.
4%
55M+
$1,352 Vol.
3%
No IPO before June 2026
$4,841 Vol.
35%
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Trader sentiment on Encore Medical's IPO closing market cap remains tightly contested, with implied probabilities near 40% for sub-$45 million valuation and 35% for no listing before June 2026, reflecting uncertainty over execution amid modest fundamentals. Recent S-1/A amendments and a free writing prospectus in early April 2026 signal active roadshow efforts for a proposed $15 million raise at $5 per share via 3 million shares on NYSE American, yet absence of firm pricing or debut confirmation—despite mid-April hype targeting May 6—fuels delay bets. Differentiators include 49% trailing-twelve-month revenue growth to $2.1 million from EU sales of its CE-marked PFO closure device, versus persistent $1.6 million net losses, high regulatory exposure from U.S. FDA pivotal trial (targeted 2027 completion), and competition from Abbott and W.L. Gore in the $1.5 billion stroke prevention segment. A pricing announcement could tip odds toward the 45M–50M bin; further postponement favors the no-IPO outcome.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Market Opened: Apr 3, 2026, 7:59 PM ET
Volume
$15,088End Date
Apr 22, 2026Market Opened
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Trader sentiment on Encore Medical's IPO closing market cap remains tightly contested, with implied probabilities near 40% for sub-$45 million valuation and 35% for no listing before June 2026, reflecting uncertainty over execution amid modest fundamentals. Recent S-1/A amendments and a free writing prospectus in early April 2026 signal active roadshow efforts for a proposed $15 million raise at $5 per share via 3 million shares on NYSE American, yet absence of firm pricing or debut confirmation—despite mid-April hype targeting May 6—fuels delay bets. Differentiators include 49% trailing-twelve-month revenue growth to $2.1 million from EU sales of its CE-marked PFO closure device, versus persistent $1.6 million net losses, high regulatory exposure from U.S. FDA pivotal trial (targeted 2027 completion), and competition from Abbott and W.L. Gore in the $1.5 billion stroke prevention segment. A pricing announcement could tip odds toward the 45M–50M bin; further postponement favors the no-IPO outcome.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volume
$15,088End Date
Apr 22, 2026Market Opened
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...Trader sentiment on Encore Medical's IPO closing market cap remains tightly contested, with implied probabilities near 40% for sub-$45 million valuation and 35% for no listing before June 2026, reflecting uncertainty over execution amid modest fundamentals. Recent S-1/A amendments and a free writing prospectus in early April 2026 signal active roadshow efforts for a proposed $15 million raise at $5 per share via 3 million shares on NYSE American, yet absence of firm pricing or debut confirmation—despite mid-April hype targeting May 6—fuels delay bets. Differentiators include 49% trailing-twelve-month revenue growth to $2.1 million from EU sales of its CE-marked PFO closure device, versus persistent $1.6 million net losses, high regulatory exposure from U.S. FDA pivotal trial (targeted 2027 completion), and competition from Abbott and W.L. Gore in the $1.5 billion stroke prevention segment. A pricing announcement could tip odds toward the 45M–50M bin; further postponement favors the no-IPO outcome.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions